We Secured Breakthrough Device Designation from FDA on PEDRA Xauron Perfusion System

Published on:
February 2, 2021
Alira Health Secures Breakthrough Device Designation from the FDA on the PEDRA Xauron Perfusion System.

BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, is proud to announce the firm’s Regulatory Affairs practice has secured a Breakthrough Device Designation from the FDA for the real-time tissue perfusion system, PEDRA Xauron Perfusion System.

“I am very excited and thankful for the opportunity to support a Breakthrough Device Designation with the PEDRA Team. This breakthrough designation will further expedite the premarket approval for an innovative technology that stands to benefit millions of patients suffering from critical limb-threatening ischemia (CLTI),” said Mary McNamara-Cullinane, Senior Vice President, Regulatory Affairs, Alira Health.

PEDRA’s real-time perfusion system is a non-invasive tool used for the treatment of critical limb-threatening ischemia (CLTI), a severe form of peripheral arterial disease (PAD). PAD is defined as a heavy blockage in the arteries of the lower extremities, which reduces blood flow.

FDA’s Breakthrough Device Program creates a pathway for patients to have more timely access to innovative medical devices by expediting their development, assessment, and review while preserving the statutory standards for premarket approval.

About PEDRA Technology, Inc.

PEDRA Technology is a medical device company that focuses on the use of tissue perfusion monitoring in the field of peripheral artery disease (PAD) and critical limb ischemia (CLI). The PEDRA™ Xauron™ Perfusion System is not currently approved for sale in the U.S. Learn more at PEDRAtech.com.

To read the press release on PR Newswire, click here.

Related news

Publications May 25, 2023
The EU Pharmaceutical Package: Introduction to Changes
Alira Health’s Regulatory experts explore how the proposed package will disrupt the European regulatory landscape and what it means for companies.
EU Pharma Regulatory
News February 21, 2023
Access and reimbursement pathways for digital health solutions and IVD devices
Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular(...)
Diagnostics Digital Therapeutics Market Access Regulatory Research and Development
Events February 10, 2023
Regulatory Roundup
We are pleased to announce that we are joining Regulatory Roundup as sponsors and speakers. This unique event is hosted by MassMEDIC, the largest regional medtech association in the United States.
Blog January 19, 2023
Medical Device Regulation in 2023: A Window of Opportunity
We spoke with our team of regulatory experts about the recent news regarding the MDR and the opportunity it presents to device manufacturers in 2023.
Medical Devices MedTech Regulatory
Blog January 11, 2023
Regulatory Strategy for Registering Rare Disease Products in the EU: What You Need to Know
Given that the regulation is likely to change considerably, drug developers may need to revisit their development strategy. In the meantime, building a strategy around these evergreen(...)
EU Rare Disease Regulatory
Blog December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
Multimedia December 17, 2022
Webinar Replay: Partnering with Patients to Streamline Trial Operations: Protocol to Regulatory Submission in 60 days
Learn how patients and patient advocacy organizations can be directly enabled as powerful partners to facilitate all stages of DCT deployment, from protocol design, recruitment, engagement(...)
Clinical Trials Patient Centricity Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.